Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 21, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of share transactions rather than a financial performance report.
Material Changes
The filing details a specific transaction on September 20, 2005, where Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust, transferred 3,578 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of these transactions on September 21, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b) regarding the notification of director and employee trust interests.
Investor Verification Points
- Verify the total number of shares transferred (3,578) and the date of the transaction (September 20, 2005).
- Confirm the involvement of the GlaxoSmithKline Employee Trust and the SmithKline Beecham Employee Share Option Plan 1991.
- Note that Directors Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop hold interests in the GSK Trust as potential beneficiaries alongside other employees.